A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
2016 ◽
Vol 34
(15_suppl)
◽
pp. TPS2082-TPS2082
◽
Keyword(s):
Phase I
◽